Vaxil Bio Ltd. VXL.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada
Vaxil Bio Ltd. is a Canadian biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product candidate is ImMucin, a MUC1 signal-peptide-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. Vaxil Bio also has pipeline candidates targeting COVID-19, tuberculosis, and monoclonal antibodies for oncology.
Key ratios
ReturnOnAssets TTM -0.16
ReturnOnAssets 2024 -0.14
ReturnOnAssets 2023 -0.13
ReturnOnAssets 2022 -0.19
ReturnOnEquity TTM -0.13
ReturnOnEquity 2024 -0.22
ReturnOnEquity 2023 -0.25
ReturnOnEquity 2022 -0.41